Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Research programme: non-nucleoside reverse transcriptase inhibitors - Medivir AB

Drug Profile

Research programme: non-nucleoside reverse transcriptase inhibitors - Medivir AB

Alternative Names: MIV-170; NNRTI research programme - Medivir AB; Non-nucleoside reverse transcriptase inhibitors research programme - Medivir AB

Latest Information Update: 09 Jul 2007

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Medivir AB
  • Class
  • Mechanism of Action Non-nucleoside reverse transcriptase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued HIV infections

Most Recent Events

  • 06 Jul 2007 Bristol-Myers Squibb terminates its licence for MIV 170
  • 13 Sep 2006 MIV 170 has been licensed to Bristol-Myers Squibb worldwide for the treatment of HIV-1 infections in adult patients
  • 28 Dec 2005 This programme is still in active development
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top